Amneal Pharmaceuticals (AMRX) Earnings Date & Reports

Key Takeaways

• Amneal reported third quarter 2026 net revenue of $862.7 million, up 10% year over year and above the roughly $812–$826 million consensus estimate.
• Adjusted diluted earnings per share (EPS) came in at $0.26, up 53% from $0.17 a year ago and ahead of the approximately $0.23 consensus.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 30% to $207 million, driven by higher gross profit and lower operating expenses.
• On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a net loss of about $22 million, or a $0.06 diluted loss per share, reflecting one-time acquisition and integration costs tied to the Kashiv deal.
• Management raised full-year 2026 guidance for a third consecutive time, lifting revenue, adjusted EBITDA, and adjusted EPS ranges.
• You can find more information about this ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see AI-driven trading strategies across the market.

Earnings Context and Why It Matters

Amneal Pharmaceuticals has built a pattern of beating expectations and raising its outlook throughout 2026, making each quarterly report a key checkpoint for investors tracking the company's momentum. The third quarter marked the first full period in which the integration of Kashiv Biosciences—a strategic acquisition that expands biosimilar capacity and pipeline—showed up in results. With growth accelerating across its Affordable Medicines and Specialty segments, this report was widely viewed as a test of whether the company could sustain double-digit revenue expansion while managing acquisition costs. For shareholders, the results offered fresh evidence on margin durability, segment mix, and the credibility of management's increasingly optimistic full-year guidance.

Reported Results

For the third quarter ended September 30, 2026, Amneal reported net revenue of $862.7 million, a 10% increase from $784.5 million in the prior-year period and ahead of consensus estimates that ranged between roughly $812 million and $826 million. Gross profit climbed to $334.1 million from $274.0 million, lifting gross margin to 38.7% from 34.9% a year earlier. Operating income nearly doubled to $95.4 million from $70.3 million.

On an adjusted basis, diluted EPS rose 53% to $0.26 from $0.17, exceeding the approximately $0.23 consensus. Adjusted EBITDA increased 30% to $207 million. On a GAAP basis, however, the company recorded a net loss of about $22 million, or a $0.06 diluted loss per share, compared with net income of roughly $2 million a year ago. The swing largely reflected $22.3 million in acquisition and integration costs related to Kashiv, plus a higher tax provision.

Segment results were broadly strong. Affordable Medicines revenue grew 19% to $547 million, helped by biosimilars, women's health patches, and new launches, while Specialty revenue rose 20% to about $150 million, led by branded products including CREXONT, the BREKIYA autoinjector, and UNITHROID. AvKARE revenue declined 17% as expected, due to a non-recurring cardiovascular product launch in the prior year.

Management also raised full-year 2026 guidance to net revenue of $3.15–$3.25 billion, adjusted EBITDA of $800–$815 million, and adjusted diluted EPS of $1.04–$1.08.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors following names like Amneal Pharmaceuticals, it offers a structured way to surface comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Despite a headline beat on adjusted EPS and revenue plus a third consecutive guidance raise, Amneal shares traded lower following the report, with the stock slipping roughly 5% from a close near $20.44 ahead of the announcement. The reaction suggests investors focused less on the top-line beat and more on the GAAP swing to a loss, the acquisition-driven costs, and fourth-quarter guidance that implied sequential moderation in revenue and adjusted EBITDA. The stock had rallied strongly into the print—up about 80% over the prior twelve months—leaving it vulnerable to profit-taking. Sentiment remains constructive on the underlying growth story, but the post-earnings move highlights sensitivity to leverage, integration expenses, and cash-flow considerations.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central theme is whether Amneal can convert its revenue momentum into durable profitability as it absorbs the Kashiv acquisition. The updated full-year guidance implies fourth-quarter revenue near $820 million and adjusted EBITDA around $190 million—both below third-quarter levels—so investors will watch whether the company can beat those embedded assumptions, particularly with a lanreotide launch on the horizon.

The integration of Kashiv remains the most important operational factor to monitor. The deal meaningfully expands biosimilar drug-substance capacity and adds a substantial pipeline, but it also introduces acquisition and integration costs and higher goodwill and intangible assets on the balance sheet. Progress on cost synergies, biosimilar approvals, and commercial launches will shape how quickly the transaction becomes accretive to the bottom line.

Margin trajectory across segments also deserves attention. Affordable Medicines and Specialty delivered double-digit growth, but AvKARE faces a difficult comparison. Investors should monitor gross margin durability, new product launch timing, and any lingering impact from the earlier flood at the company's India site. Leverage and cash-flow trends will also remain in focus as management works toward its stated goal of reducing net leverage below 3x by 2028.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations